Atlas Trials

PT Bio Farma

44 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch PT Bio Farma

RecordFirmDate
A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations (NCT07647107)PT Bio Farma2026-08-01
Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) (NCT05482295)PT Bio Farma2025-09-01
Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV (NCT06921460)PT Bio Farma2025-06-15
Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants (NCT06690515)PT Bio Farma2025-03-01
Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination (NCT06690502)PT Bio Farma2023-12-18
Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine (NCT05933278)PT Bio Farma2023-07-25
Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients (NCT06114641)PT Bio Farma2023-06-01
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age (NCT05727215)PT Bio Farma2023-02-28
Post Marketing Surveillance of Diphtheria Antitoxin (DAT) (NCT06053853)PT Bio Farma2023-01-31
Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in Bandung (NCT05657769)PT Bio Farma2022-11-12
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine (NCT05525208)PT Bio Farma2022-09-01
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine (NCT05433285)PT Bio Farma2022-06-07
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine (NCT05313035)PT Bio Farma2022-04-13
Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma) (NCT06111911)PT Bio Farma2022-04-01
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018 (NCT05228613)PT Bio Farma2022-02-16
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (NCT05067894)PT Bio Farma2021-12-10
Safety and Tuberculin Conversion Following BCG Vaccination (NCT05124340)PT Bio Farma2021-12-01
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia (NCT05037227)PT Bio Farma2021-09-02
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian (NCT04741828)PT Bio Farma2021-05-03
Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates (NCT04185545)PT Bio Farma2020-10-30
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine (NCT04508075)PT Bio Farma2020-08-10
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) (NCT04051268)PT Bio Farma2020-03-02
Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children (NCT04188223)PT Bio Farma2019-12-03
Protectivity and Safety Following Recombinant Hepatitis B Vaccine (NCT03919578)PT Bio Farma2019-09-11
Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) (NCT04183114)PT Bio Farma2019-09-03
Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates (NCT03462108)PT Bio Farma2018-04-09
Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population (NCT03336593)PT Bio Farma2017-11-21
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children (NCT03680417)PT Bio Farma2017-11-16

Track PT Bio Farma automatically

Every clearance here is in the API, with alerts when new ones post.